Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (NYSE: PLX) Delayed: 2.22 +0.06 (2.78%)
Previous Close $2.16    52 Week High $1.11 
Open $2.15    52 Week Low $0.41 
Day High $2.23    P/E N/A 
Day Low $2.13    EPS $-0.29 
Volume 64,905       

PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (NYSE: PLX) Delayed: 2.22 +0.06 (2.78%)
Previous Close $2.16    52 Week High $1.11 
Open $2.15    52 Week Low $0.41 
Day High $2.23    P/E N/A 
Day Low $2.13    EPS $-0.29 
Volume 64,905